SEC-sourced researchBeta

VRTX

VERTEX PHARMACEUTICALS INC / MA

US markets

Data passport

CIK: 0000875320
Exchange: Nasdaq
Business activity: — · SIC 2834
Financial inputs: 6/6
Filing date: Sep 10, 2026
SEC registry record: Operating company

Last updated: Oct 6, 2026, 3:03 AM UTCSEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Chart metric

VRTX · Exact amounts and source periods · USD
Period end	Revenue	Filing date
December 2023	9,869,200,000.0000	Feb 13, 2026
December 2024	11,020,100,000.0000	Feb 13, 2026
December 2025	12,001,300,000.0000	Feb 13, 2026

Annual periods · USD

Period end	Revenue	Net income	Operating cash flow	Total assets	Total liabilities	Filing date
December 2025	12,001,300,000.0000	3,953,200,000.0000	3,631,400,000.0000	25,643,000,000.0000	6,977,200,000.0000	Feb 13, 2026
December 2024	11,020,100,000.0000	-535,600,000.0000	-492,600,000.0000	22,533,200,000.0000	6,123,600,000.0000	Feb 13, 2026
December 2023	9,869,200,000.0000	3,619,600,000.0000	3,537,300,000.0000	—	—	Feb 13, 2026

Financial inputs behind the calculation

Financial inputs	USD	Period end	Filing date	Form
RevenueRevenueFromContractWithCustomerExcludingAssessedTax	$12B	December 2025	Feb 13, 2026	10-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax	$11.02B	December 2024	Feb 13, 2026	10-K
Net incomeNetIncomeLoss	$3.95B	December 2025	Feb 13, 2026	10-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities	$3.63B	December 2025	Feb 13, 2026	10-K
Total assetsAssets	$25.64B	December 2025	Feb 13, 2026	10-K
Total liabilitiesLiabilities	$6.98B	December 2025	Feb 13, 2026	10-K

New filings

Explore methodology ↗